Figure S3 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

Immunophenotyping profile of SALL4-TCR T cells. (A) Memory phenotype: TN/TSCM (CD45RA+, CD62L+), TEMRA (CD62L-, CD45RA+), TCM (CD62L+, CD45RA-) and TEM (CD45RA-, CD62L-) subset distribution in unstimulated and S9V stimulated primary T cells redirected to express SALL4-TCR (n=4). (B) t-SNE representation of the expression of extracellular activation markers and immune checkpoint molecules (CD69, HLA-DR, 4-1BB, PD1, LAG3, and TIM3) of unstimulated and stimulated SALL4-TCR T cells. (C) Expression of CD69, HLA-DR, 4-1BB, PD1, LAG3, and TIM3 on unstimulated and stimulated SALL4-TCR T cells. (D) Co-expression of pairs of checkpoint markers (PD1, TIM3, LAG3, and TIGIT). (E) Expression of chemokine receptors CXCR2, CXCR3, CXCR4, CXCR6, CX3CR1 and CCR4 on SALL4-TCR T cells. (F) Quantification of released analytes including TNF-α, IFNγ, granzyme A, granzyme B, IL2, IL4, and perforin assessed by Legendplex analysis in cell culture supernatants of SALL4-TCR T cells previously stimulated or not during 5h with S9V peptide at different concentration [0-10µg/mL] (n = 4).